SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
APLM

Apollomics Inc. (NASDAQ:APLM)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$15.54-$1.16 (-6.92%)
 
Market cap
$45.3M
Insider Score
Health Score
Analyst consensus
Listed since
Nov 26, 2021
Market Cap$45.28M-8.6%
Revenue (ttm)$0+199.1%
Net Income-$7.22M+91.4%
EPS-$2.48+30.0%
Shares Out2.91M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,067
Open$16.00
Previous Close$16.69
Day's Range$15.54 - $16.51
52-Week Range$12.58 - $28.29
Beta1.56
AnalystsBuy
Price Targetn/a
Earnings DateApr 1, 2027
-6.77% (1D)
No price history available.

About APLM

Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.

Address
989 East Hillsdale Blvd, Foster City, CA, 94404, US
Market Cap
45 million
Employees
14
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$8.25M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Distressed
From APLM’s reported statements · Q2 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-6.92%
5 Days
-10.20%
1 Month
-29.39%
6 Months
+10.26%
1 Year
-8.56%

$APLM stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in APLM holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by APLM's directors and management

Net Shares Purchased by Insiders−600k−300k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

APLM Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New APLM patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to APLM from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from APLM’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
100% of score
50.81
Analyst Ratings
No data yet
—
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
5
Sells
0
Buy Value
$8.25M
Distinct Buyers
3

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.